Bitwise MARA Option Income Strategy ETF (NYSEARCA:IMRA – Get Free Report) insider Helen Louise Collins sold 5,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total transaction of $219,000.00. Following the completion of the sale, the insider directly owned 25,000 shares of the company’s stock, valued at $1,095,000. The trade was a 16.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Helen Louise Collins also recently made the following trade(s):
- On Friday, April 17th, Helen Louise Collins sold 5,000 shares of Bitwise MARA Option Income Strategy ETF stock. The shares were sold at an average price of $47.67, for a total transaction of $238,350.00.
- On Wednesday, March 25th, Helen Louise Collins sold 40,000 shares of Bitwise MARA Option Income Strategy ETF stock. The stock was sold at an average price of $35.10, for a total transaction of $1,404,000.00.
Bitwise MARA Option Income Strategy ETF Stock Performance
Shares of IMRA stock traded up $0.41 during midday trading on Monday, reaching $17.64. 617 shares of the company were exchanged, compared to its average volume of 5,386. The company’s 50 day moving average price is $16.49 and its two-hundred day moving average price is $15.80. The company has a market cap of $3.35 million, a P/E ratio of 352.80 and a beta of 2.88. Bitwise MARA Option Income Strategy ETF has a 12 month low of $11.99 and a 12 month high of $54.94.
Bitwise MARA Option Income Strategy ETF Company Profile
IMARA Inc, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas.
See Also
- Five stocks we like better than Bitwise MARA Option Income Strategy ETF
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Receive News & Ratings for Bitwise MARA Option Income Strategy ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bitwise MARA Option Income Strategy ETF and related companies with MarketBeat.com's FREE daily email newsletter.
